Trial · NCT04680052
Adverse events630
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 630
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Abdominal pain | Gastrointestinal disorders | Tafasitamab + Rituximab + Lenalidomide | 25 | 327 | 33 |
| other | Abdominal pain | Gastrointestinal disorders | Placebo + Rituximab + Lenalidomide | 28 | 325 | 30 |
| other | Abdominal pain | Gastrointestinal disorders | Total | 53 | 652 | 63 |
| other | Alanine aminotransferase increased | Investigations | Tafasitamab + Rituximab + Lenalidomide | 19 | 327 | 28 |
| other | Alanine aminotransferase increased | Investigations | Placebo + Rituximab + Lenalidomide | 23 | 325 | 36 |
| other | Alanine aminotransferase increased | Investigations | Total | 42 | 652 | 64 |
| other | Anaemia | Blood and lymphatic system disorders | Tafasitamab + Rituximab + Lenalidomide | 53 | 327 | 97 |
| other | Anaemia | Blood and lymphatic system disorders | Placebo + Rituximab + Lenalidomide | 46 | 325 | 73 |
| other | Anaemia | Blood and lymphatic system disorders | Total | 99 | 652 | 170 |
| other | Arthralgia | Musculoskeletal and connective tissue disorders | Tafasitamab + Rituximab + Lenalidomide | 24 | 327 | 25 |
| other | Arthralgia | Musculoskeletal and connective tissue disorders | Placebo + Rituximab + Lenalidomide | 27 | 325 | 36 |
| other | Arthralgia | Musculoskeletal and connective tissue disorders | Total | 51 | 652 | 61 |
| other | Asthenia | General disorders | Tafasitamab + Rituximab + Lenalidomide | 44 | 327 | 58 |
| other | Asthenia | General disorders | Placebo + Rituximab + Lenalidomide | 35 | 325 | 48 |
| other | Asthenia | General disorders | Total | 79 | 652 | 106 |
| other | Back pain | Musculoskeletal and connective tissue disorders | Tafasitamab + Rituximab + Lenalidomide | 32 | 327 | 41 |
| other | Back pain | Musculoskeletal and connective tissue disorders | Placebo + Rituximab + Lenalidomide | 18 | 325 | 21 |
| other | Back pain | Musculoskeletal and connective tissue disorders | Total | 50 | 652 | 62 |
| other | Bronchitis | Infections and infestations | Tafasitamab + Rituximab + Lenalidomide | 17 | 327 | 21 |
| other | Bronchitis | Infections and infestations | Placebo + Rituximab + Lenalidomide | 14 | 325 | 14 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04680052/events